Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Last trade$436.10
Day change-$10.18 (-2.28%)
Day range$432.92 – $447.95
Volume567,066
Market cap$96.42B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$96.42B
Price / earnings
18.76×
Price / book
2.16×
Price / sales
0.48×
EV / sales
0.58×
EV / EBITDA
12.72×
Profitability
Earnings per share
$23.79
Return on assets
4.02%
Return on equity
11.5%
Dividend yield
1.55%
Liquidity and leverage
Debt / equity
0.69×
Current ratio
3.51×
Quick ratio
3.51×
Cash ratio
1.04×
Cash flow
Price / cash flow
12.69×
Price / free cash flow
14.8×
Free cash flow
$6.51B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ELV, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$51.43B
$50.47B
$50.18B
$49.75B
$50.71B
$49.78B
$48.89B
$45.44B
Cost of revenue
$37.78B
$37.02B
$35.62B
$38.07B
$38.14B
$36.71B
$35.31B
$33.5B
Gross profit
$13.65B
$13.45B
$14.57B
$11.68B
$12.57B
$13.07B
$13.58B
$11.94B
Selling, general and administrative
$5.75B
$5.55B
$6.33B
$5.42B
$5.27B
$5B
$5.3B
$4.8B
Research and development
—
—
—
—
—
—
—
—
Total operating expenses
$49.28B
$48.17B
$47.52B
$49.17B
$48.95B
$47.14B
$45.75B
$44.5B
Operating income
$2.15B
$2.3B
$2.66B
$581M
$1.76B
$2.63B
$3.14B
$946M
Interest expense
-$358M
-$364M
-$357M
-$366M
-$351M
-$341M
-$344M
-$340M
Income before taxes
$1.79B
$1.94B
$2.3B
$215M
$1.41B
$2.29B
$2.8B
$606M
Income taxes
$451M
$483M
$544M
-$331M
$219M
$548M
$613M
$193M
Net income
$1.34B
$1.45B
$1.76B
$546M
$1.19B
$1.74B
$2.18B
$413M
Net income attributable to common shareholders
$1.37B
$1.46B
$1.76B
$547M
$1.19B
$1.74B
$2.18B
$418M
EBITDA
$2.52B
$2.67B
$3.02B
$987M
$2.14B
$3.01B
$3.51B
$1.34B
Basic earnings per share
$6.30
$6.74
$8.03
$2.47
$5.32
$7.74
$9.64
$1.83
Diluted earnings per share
$6.27
$6.71
$8.00
$2.47
$5.32
$7.72
$9.61
$1.81
Recent news
Company coverage with links to the original publishers.
Elevance Health expects Medicaid margins to improve in 2027 through higher reimbursement rates and cost management, with Q3 Medicaid revenues reaching $15 billion. However, rate increases remain uneven across states and may not fully offset elevated medical costs. Peers Centene and Molina face similar pressures, with mixed results in converting premium growth to profitability.
Humana Inc. has launched a new oncology care model in partnership with Evolent Health and American Oncology Network across eight states. The initiative streamlines prior authorization for qualifying practices, uses EHR analytics and provider scorecards to promote evidence-based cancer treatment, and aims to improve care coordination while reducing specialty care spending. HUM stock has rallied 82.2% over the past year but trades at a premium valuation of 29.08x forward P/E versus the industry average of 15.72x.
In a comparison of two Medical Services stocks, Elevance Health (ELV) and Revvity (RVTY), both holding a Zacks Rank #2 (Buy), ELV emerges as the superior value option. ELV features a lower forward P/E ratio of 14.97 compared to RVTY's 29.34, a better PEG ratio of 2.08 versus 2.79, and a lower P/B ratio of 2.07 versus 2.44. These metrics contribute to ELV's Value grade of A compared to RVTY's C grade.
Humana (HUM) reported Q3 2026 adjusted loss of $0.70 per share, beating estimates, with revenues surging 26.4% to $40.83B driven by Medicare membership growth and higher premiums. The company raised its 2026 adjusted EPS guidance to at least $9.50 and projects revenues of at least $160B, though rising benefit costs and deteriorating benefit ratios remain concerns.
Humana is set to report Q3 2026 results on Nov. 6 with an expected loss of $1.03 per share on $40.46B in revenues. While premiums are projected to rise 26% and Medicare to grow 30.1%, the company faces 25.4% higher operating costs and a deteriorating benefits expense ratio of 94.3% (up from 91.1% year-ago), which is expected to pressure bottom-line performance. However, the company has an Earnings ESP of +3.33% and Zacks Rank #2, suggesting a likely earnings beat.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$1.72 per share
Declared
Oct 20, 2026
Ex-dividend
Dec 4, 2026
Pay date
Dec 18, 2026
Ex-dividend
Amount / share
Pay date
Type
Sep 10, 2026
$1.72
Sep 25, 2026
recurring
Jun 10, 2026
$1.72
Jun 25, 2026
recurring
Mar 10, 2026
$1.72
Mar 25, 2026
recurring
Dec 5, 2025
$1.71
Dec 19, 2025
recurring
Sep 10, 2025
$1.71
Sep 25, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.